Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Sotomayor Nomination Lacks Controversy GOP Had Hoped To Generate
Supreme Court nominee Judge Sonia Sotomayor has not become the "political lightning rod" Republican senators hoped for, leaving doubt among some members of the GOP that the nomination process will be controversial enough to help them or hurt Democrats in the 2010 elections, Politico reports. Sen. John Thune (R-S.D.) said that "at least so far" Sotomayor "doesn"t have the punch put there in terms of fundraising and recruiting." Thune said that one reason the GOP response to Sotomayor has been relatively quiet is that she is nominated to replace retiring Justice David Souter, rather than a more conservative justice. "When one of the conservatives leaves the court, then I think you"ll have a huge fight, and I think that will be very galvanizing," Thune said. Similarly, Sen. John Cornyn (R-Texas), a member of the Senate Judiciary Committee and chair of the National Republican Senatorial Committee, said he does not foresee Sotomayor"s nomination becoming a major issue in the 2010 campaigns. Sen. Jeff Sessions (R-Ala.), the ranking Republican on the Judiciary Committee, said that the GOP would use witnesses at Sotomayor"s confirmation hearing to present some opposition arguments (Raju, Politico, 6/22). Sessions and other Senate Republicans are preparing a series of speeches to highlight their concerns about Sotomayor, the Wall Street Journal reports. According to a Senate Republican aide, the focus of Sessions" speech will be Sotomayor"s role in the group LatinoJustice PRLDEF, for which she served as a board member from 1980 to 1992. Unless new information surfaces, there are few doubts that Sotomayor will be confirmed, the Journal reports (Bravin, Wall Street Journal, 6/22).
generic viagra online
UK's NICE Recommends Use Of Erbitux For Metastatic Colorectal Cancer Patients
The United Kingdom"s National Institute for Health and Clinical Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending the use of the drug Erbitux® (cetuximab) in combination with chemotherapy as a 1st-line treatment for patients with metastatic (advanced) colorectal cancer (mCRC) who have met specific additional criteria1 - presenting the possibility of potentially curative surgery.2 The treatment is recommended for patients in whom the cancer has spread only to the liver and who have normal or "wild-type" KRAS tumors.1 In the UK, a recommendation by NICE is a prerequisite for funding of a medical treatment by the National Health Service.
News of the day
PharmaMar Announces The Initiation Of Phase I Clinical Trials With PM1183, A New Antitumor Compound
PharmaMar SA (Grupo Zeltia, ZEL.MC) announces the initiation of Phase I clinical trials with PM1183, a new antitumor compound developed by
Medical Devices

Pharmacies Urged To Register From 1 - 31 July 2009 To Receive Early-bird Payment

Community pharmacies are urged to register to participate in Phase 2 of the Dose Administration Aids (DAA) and Patient Medication Profile (PMP) programs. Pharmacies registering from 1 to 31 July 2009 will be eligible for the full incentive payment of $2,250 for DAA and $1,250 for PMP (+GST). While registrations will still be accepted after July, a lesser incentive payment will apply. "We need as many pharmacies as possible to participate in Phase 2 of these programs to ensure the ongoing and sustainable delivery of these important services," said Mr Kos Sclavos, .National President of the Pharmacy Guild of Australia. In response to feedback from community pharmacy, the DAA and PMP programs, managed by the Pharmacy Guild of Australia, have been reviewed and revamped to make participation in them easier and systems more user-friendly. The amount of time and data required has been reduced, and the payment deadlines have been simplified. "DAA and PMP services offer clear benefits to patients and the wider community. Patients have better medication management, and better continuity of care. The community have fewer hospitalizations associated with medicine misadventure and delayed admissions to aged care services," said Mr Warwick Plunkett, National President of the Pharmaceutical Society of Australia. Medication misadventure is estimated to cost the health sector $380 million a year ( "Improving Medication Safety" by the Australian Council for Safety and Quality in Healthcare, 2002). The DAA program allows pharmacist to organise patients" medicines into weekly blister packs. The PMP allows pharmacists to produce a comprehensive profile of the patient"s medicines, including information about instructions for use, appearance and generic substitution availability. The DAA and PMP Programs are funded under the Better Community Health Initiative of the Fourth Community Pharmacy Agreement by the Australian Government Department of Health and Ageing. In mid-June, all pharmacies will receive a new Pharmacy Readiness Kit with information and new PMP promotional materials to support their participation. For more information visit the Guild website at http://www.guild.org.au Pharmaceutical Society of Australia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009